Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 249

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial

Mancardi, Giovanni L., Sormani, Maria P., Gualandi, Francesca, Saiz, Albert, Carreras, Eric, Merelli, Elisa, Donelli, Amedea, Lugaresi, Alessandra, Di Bartolomeo, Paolo, Rottoli, Maria R., Rambaldi, Alessandro, Amato, Maria P., Massacesi, Luca, Di Gioia, Massimo, Vuolo, Luisa, Currò, Daniela, Roccatagliata, Luca, Filippi, Massimo, Aguglia, Umberto, Iacopino, Pasquale, Farge, Dominique, Saccardi, Riccardo, For the ASTIMS Haemato-Neurological Collaborative Group, On behalf of the Autoimmune Disease Working Party (ADWP) of the European Group for Blood and Marrow Transplantation (EBMT), Capello, E., Uccelli, A., Bagigalupo, F., Repice, A.M., Portaccio, E., Barillaro, A., Russo, C., De Luca, G., Farina, D., Tartaro, A., Blanco, Y., Berenguer, J., Bresciani, P., Cuoghi, A., Zonari, P. · 2015 · Neurology

Abstract

OBJECTIVE: To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured by MRI. METHODS: We conducted a multicenter, phase II, randomized trial including patients with secondary progressive or relapsing-remitting MS, with a documented increase in the last year on the Expanded Disability Status Scale, in spite of conventional therapy, and presence of one or more gadolinium-enhancing (Gd+) areas. Patients were randomized to receive intense immunosuppression (mobilization with cyclophosphamide and filgrastim, conditioning with carmustine, cytosine-arabinoside, etoposide, melphalan, and anti-thymocyte globulin) followed by AHSCT or MTX 20 mg every month for 6 months. The primary endpoint was the cumulative number of new T2 lesions in the 4 years following randomization. Secondary endpoints were the cumulative number of Gd+ lesions, relapse rate, and disability progression. Safety and tolerability were also assessed. Twenty-one patients were randomized and 17 had postbaseline evaluable MRI scans. RESULTS: AHSCT reduced by 79% the number of new T2 lesions as compared to MTX (rate ratio 0.21, p = 0.00016). It also reduced Gd+ lesions as well as the annualized relapse rate. No difference was found in the progression of disability. CONCLUSION: Intense immunosuppression followed by AHSCT is significantly superior to MTX in reducing MRI activity in severe cases of MS. These results strongly support further phase III studies with primary clinical endpoints. The study was registered as EUDRACT No. 2007-000064-24.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000001329

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 249

Metadata

Authors
Mancardi, G. L., Sormani, M. P., Gualandi, F., Saiz, A., Carreras, E., Merelli, E., Donelli, A., Lugaresi, A., Di Bartolomeo, P., Rottoli, M. R., Rambaldi, A., Amato, M. P., Massacesi, L., Di Gioia, M., Vuolo, L., Currò, D., Roccatagliata, L., Filippi, M., Aguglia, U., Iacopino, P., Farge, D., Saccardi, R., For the ASTIMS Haemato-Neurological Collaborative Group, O. B. O. T. A. D. W. P. (. O. T. E. G. F. B. A. M. T. (., Capello, E., Uccelli, A., Bagigalupo, F., Repice, A. M., Portaccio, E., Barillaro, A., Russo, C., De Luca, G., Farina, D., Tartaro, A., Blanco, Y., Berenguer, J., Bresciani, P., Cuoghi, A., & Zonari, P.
Venue
Neurology
Published
2015-03-10
Volume
84
Issue
10
Pages
981-988
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2030921615
Cited by
249
References
1
FWCI
24.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. https://app.cochat.ai/papers/10.1212/wnl.0000000000001329
The paper
Mancardi, G. L., Sormani, M. P., Gualandi, F., Saiz, A., Carreras, E., Merelli, E., Donelli, A., Lugaresi, A., Di Bartolomeo, P., Rottoli, M. R., Rambaldi, A., Amato, M. P., Massacesi, L., Di Gioia, M., Vuolo, L., Currò, D., Roccatagliata, L., Filippi, M., Aguglia, U., . . . Zonari, P. (2015). Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. Neurology. https://doi.org/10.1212/wnl.0000000000001329

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.